Andy Schmeltz
Andy Schmeltz is the Global President and General Manager of Pfizer Oncology. In this role, he leads the team responsible for Pfizer's industry-leading portfolio of 23 innovative cancer medicines and biosimilars that reached more than 568,000 people living with cancer worldwide in 2019.
Under Andy’s leadership, the business has experienced tremendous and continued growth. In 2019, he championed the $11.4 billion acquisition of Array BioPharma Inc. to strengthen the division's leadership in cancer care and expand the company's portfolio into additional areas of unmet medical need.
Beyond oncology, Andy has held numerous leadership positions in different therapeutic areas during his 25 years in the healthcare industry, including cardiovascular-metabolic, neuroscience and pain, infectious disease, inflammation and immunology, as well as consumer health. Prior to his current role, he was Senior Vice President of Pfizer’s Patient & Health Impact division, where he was accountable for demonstrating the value of Pfizer’s medicines and vaccines as well as ensuring people around the world gain affordable, timely access to these products. Before joining Pfizer, Andy worked at Abbott Laboratories.
Throughout his career, Andy has led diverse teams that consistently deliver strong results by setting a compelling vision that instills purpose and creating an open culture where people feel inspired and can be their best selves. Andy believes that by building a trusted environment where people can stretch for excellence – business and society will thrive together.
Andy has a Bachelor of Arts in economics from Columbia University, and his Master of Business Administration from the University of Chicago's Booth School of Business.